Maegim한국어

헬릭스미스

084990KOSDAQSector: Pharma & Biotech
₩3,340 1.37%Market cap ₩153.9BAs of Jul 21, 2026 close · updated once daily
B
Grade B58 ptsTop 38% of 2,523 stocks
Financial strength
67.0
Growth momentum
46.8
Price attractiveness
55.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

67.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
1.2%
Above median · Top 0.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
10471.9%
Above median · Top 0.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-381.0%
Below median · Top 87.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-0.3%
Above median · Top 43.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

46.8
How much did revenue grow in a year?
Revenue growth (YoY)
-47.8%
Below median · Top 95.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-2.5%
Below median · Top 73.9% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
44.9%
Above median · Top 23% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
81.2%
Above median · Top 20.7% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

55.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Above median · Top 45.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.08x
Above median · Top 43.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15